RNAZ (TransCode Therapeutics) Institutional Ownership: 3.25% (As of Jul. 08, 2026)


RNAZ TransCode Therapeutics Inc RNAZ
34 GF Score
Price $7.84
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics Institutional Ownership?

TransCode Therapeutics RNAZ -5.91% 34 Institutional Ownership is 3.25% as of Jul. 08, 2026. GuruFocus rates RNAZ with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, TransCode Therapeutics's institutional ownership is 3.25%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, TransCode Therapeutics's Insider Ownership is 14.86%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, TransCode Therapeutics's Float Percentage Of Total Shares Outstanding is 100.03%.

TransCode Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for TransCode Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics Institutional Ownership Chart

TransCode Therapeutics Historical Data

The historical data trend for TransCode Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 17.37 18.64 18.64 0.78 0.78 1.02 1.41 1.40 1.40 1.28
RNAZ
34GF Score
TransCode Therapeutics Inc RNAZ
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TransCode Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 3.25% mean?
TransCode Therapeutics (RNAZ) has a Institutional Ownership of 3.25% as of Jul. 08, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on TransCode Therapeutics and its competitors.
Is TransCode Therapeutics' Institutional Ownership too high?
TransCode Therapeutics' current Institutional Ownership is 3.25%. Overall, TransCode Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' Institutional Ownership compare to ENSC and ALZN?
TransCode Therapeutics' Institutional Ownership of 3.25% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current Institutional Ownership is 3.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current Institutional Ownership of 3.25%. The current Institutional Ownership is 3.25%. TransCode Therapeutics' overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current Institutional Ownership is 3.25% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
34GF Score

Get the complete analysis for RNAZ

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.84
Price